Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
SGMO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.30 - $3.18
Previous CloseN/A
Volume2.84M
Average Volume (3M)4.49M
Market Cap
$239.94M
Enterprise Value$174.15M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.66
Next Earnings
May 08, 2025EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding208,646,870
10 Day Avg. Volume3,795,283
30 Day Avg. Volume4,491,263
Standard Deviation0.35
R-Squared0.04
Alpha0.00250
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4.59
Price to Cash Flow (P/CF)5.10
P/FCF Ratio5.20
Enterprise Value/Market Cap0.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.84
Enterprise Value/Ebitda-1.39
Forecast
1Y Price Target
$5.80Price Target Upside427.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Bulls Say, Bears Say
Bulls Say
Accelerated ApprovalThe positive eGFR slope for the first 23 patients is promising and could support potential accelerated approval.
Collaboration AgreementManagement expects a collaboration agreement on isaralgagene civaparvovec, which should provide a non-dilutive source of funding for the neurology-focused pipeline.
Neurology-focused PipelineThe neurology-focused pipeline, including partnerships with Genentech and Astellas, is progressing on track and underpins the valuation.
Bears Say
Cash Overhang RiskPFE's decision increases cash overhang risk for SGMO, because the company will no longer be eligible for ~$70M milestone payment for BLA filing.
Hemophilia A ProgramSGMO is down -49% after they announced partner PFE will not file BLA for hemA gene tx.
Investor ExpectationsSGMO stock is likely down because investors were assuming the regulatory filing milestone payment from PFE was a high probability of success event.
---
Ownership Overview
2.46% Insiders
16.44% Mutual Funds
7.24% Other Institutional Investors
66.15% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SGMO FAQ
What was Sangamo Biosciences’s price range in the past 12 months?
Sangamo Biosciences lowest stock price was $0.30 and its highest was $3.18 in the past 12 months.
What is Sangamo Biosciences’s market cap?
Sangamo Biosciences’s market cap is $239.94M.
When is Sangamo Biosciences’s upcoming earnings report date?
Sangamo Biosciences’s upcoming earnings report date is May 08, 2025 which is in 76 days.
How were Sangamo Biosciences’s earnings last quarter?
Currently, no data Available
Is Sangamo Biosciences overvalued?
According to Wall Street analysts Sangamo Biosciences’s price is currently Undervalued.
Does Sangamo Biosciences pay dividends?
Sangamo Biosciences does not currently pay dividends.
What is Sangamo Biosciences’s EPS estimate?
Sangamo Biosciences’s EPS estimate is -0.09.
How many shares outstanding does Sangamo Biosciences have?
Sangamo Biosciences has 208,646,870 shares outstanding.
What happened to Sangamo Biosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sangamo Biosciences?
Currently, no hedge funds are holding shares in SGMO
---
Sangamo Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.80 (427.27% Upside)
$5.80 (427.27% Upside)
Blogger Sentiment
Bullish
SGMO Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-20.28%
12-Months-Change
Fundamentals
Return on Equity
-156.42%
Trailing 12-Months
Asset Growth
-49.36%
Trailing 12-Months
Company Description
Sangamo Biosciences
Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
---
SGMO Company Deck
---
SGMO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was positive, highlighting significant regulatory and clinical advancements, as well as strategic partnerships, despite the financial constraints posed by a limited cash runway.Read More>---
SGMO Stock 12 Month Forecast
Average Price Target
$5.80
▲(427.27% Upside)
Technical Analysis
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering SGMO
1 Year
1 Year Success Rate
8/18 ratings generated profit
1 Year Average Return
+36.57%
reiterated a buy rating 15 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +36.57% per trade.
---